Counteracting the dysregulation of specific ABC transporters is emerging as a new therapeutic approach for some neurodegenerative diseases, such as AD, PD, and even extremely rare diseases such as frontotemporal dementia (FTD) in which ABCA2, ABCA3, ABCA4, ABCA7, ABCA9, ABCA10, and ABCA13 expression was found to be altered in patients with FTD with TDP-43 [180]. This evidence concerns the gene ABCA7 and Alzheimer disease.